Tags

Type your tag names separated by a space and hit enter

Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Am Surg. 2016 Sep; 82(9):807-14.AS

Abstract

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71-1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC.

Authors+Show Affiliations

Department of Surgery, NorthShore University Health System-University of Chicago, Evanston, Illinois, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27670568

Citation

Suman, Paritosh, et al. "Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma." The American Surgeon, vol. 82, no. 9, 2016, pp. 807-14.
Suman P, Wang CH, Moo-Young TA, et al. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. Am Surg. 2016;82(9):807-14.
Suman, P., Wang, C. H., Moo-Young, T. A., Prinz, R. A., & Winchester, D. J. (2016). Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. The American Surgeon, 82(9), 807-14.
Suman P, et al. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. Am Surg. 2016;82(9):807-14. PubMed PMID: 27670568.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. AU - Suman,Paritosh, AU - Wang,Chi-Hsiung, AU - Moo-Young,Tricia A, AU - Prinz,Richard A, AU - Winchester,David J, PY - 2016/9/28/entrez PY - 2016/9/28/pubmed PY - 2017/1/31/medline SP - 807 EP - 14 JF - The American surgeon JO - Am Surg VL - 82 IS - 9 N2 - There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71-1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC. SN - 1555-9823 UR - https://www.unboundmedicine.com/medline/citation/27670568/Timing_of_Adjuvant_Radioactive_Iodine_Therapy_Does_Not_Affect_Overall_Survival_in_Low__and_Intermediate_Risk_Papillary_Thyroid_Carcinoma_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=0003-1348&volume=82&issue=9&spage=807&aulast=Suman DB - PRIME DP - Unbound Medicine ER -